Workflow
林园投资205号私募产品
icon
Search documents
林园旗下产品净值7毛6被投资者吐槽,白酒医药打法失灵?大V现分歧
Xin Lang Ji Jin· 2025-09-30 10:38
Core Viewpoint - The performance of Lin Yuan's private equity fund products has sparked significant discussion, particularly regarding the substantial losses experienced by some funds, highlighting the challenges faced in the current market environment [1][3][5]. Fund Performance Summary - Lin Yuan Investment No. 173, established in October 2020, has a net value of 0.7598 as of September 26, 2023, reflecting a cumulative loss of 24% since inception and a loss of 3.7% year-to-date [3][4]. - The fund's holder reported a floating loss of 605,200 yuan, equating to a 37.82% loss during the holding period [1]. - Other funds under Lin Yuan's management have also reported negative returns this year, with 19 products underperforming compared to the CSI 300 index, and 6 of these funds showing losses [5]. Market Reactions and Commentary - Financial commentators have expressed mixed sentiments regarding Lin Yuan's investment strategy, with some defending his approach to value investing despite current losses, while others criticize the performance of his funds [1][5]. - Lin Yuan has acknowledged the challenges in the market, particularly in traditional sectors like liquor and pharmaceuticals, and noted that his recent investments in technology stocks were minimal and largely passive [5].